The pruritus therapeutic market has seen considerable growth due to a variety of factors.
• In recent times, the market size for pruritus therapy has experienced robust growth. The market, which is projected to expand from $14.29 billion in 2024 to $15.43 billion in 2025, is set to display a compound annual growth rate (CAGR) of 8.0%. The notable growth observed in the historic period can be ascribed to factors such as the rising occurrence of pruritus, progress in research and development, an expanding elderly population, the enhancement of healthcare infrastructure, heightened patient awareness, and collaborative partnerships.
The Pruritus Therapeutic market is expected to maintain its strong growth trajectory in upcoming years.
• There is an anticipation of significant expansion in the pruritus therapeutic market size in the upcoming years. It is projected to escalate to $22.02 billion by 2029, experiencing a compound annual growth rate (CAGR) of 9.3%.
Variables contributing to the growth during the forecast period encompass ongoing research and advancement, growth of emerging markets, increased healthcare spending, trend towards personalized medicine, and regulatory backing for innovation. Foreseen trends during the forecast period involve the integration of telemedicine and digital health, advancements in technology, telehealth and digital health solutions, global regulatory landscapes, biologics and immunomodulators, and patient-focused strategies.
The rising occurrences of skin ailments are playing a major role in propelling the pruritus therapeutic market. The term 'skin conditions' encompasses a variety of dermatological disorders, including acne, eczema, skin cancer, psoriasis, and vitiligo, all of which impact the skin. As pruritus is a prevailing symptom in most skin diseases, pruritus therapeutics are frequently employed as a part of the treatment regime. For example, the American Academy of Dermatology Association, a US-based dermatology association, stated in April 2022 that melanoma is anticipated to result in the death of 7,650 individuals in 2022, composed of 5,080 males and 2,570 females. Moreover, the American Cancer Society, a voluntary organization based in the US, reported in January 2023 that an estimated 97,610 fresh cases of melanoma are predicted to be detected in the United States in 2023, with approximately 58,120 occurring in men and 39,490 in women. Thus, the increasingly frequent instances of skin conditions act as a catalyst for the pruritus therapeutic market.
The pruritus therapeutic market covered in this report is segmented –
1) By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Others Types
2) By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
3) By Application: External Use, Oral, Injection
4) By End Use: Hospitals, Clinics, Other Uses
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetics: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
5) By Immunosuppressants: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus, Pimecrolimus
7) By Other Types: Antidepressants, Phototherapy Treatments, Herbal Remedies
In the pruritus therapeutic market, product innovation is becoming increasingly popular. This trend sees leading market players dedicating their efforts to the creation of novel medications and treatments for pruritus and similar ailments. An example of this occurred in August 2022, when Japanese pharmaceutical company Maruho Co., Ltd released an anti-IL-31 receptor, a humanised monoclonal antibody Mitchga Subcutaneous Injection 60 mg Syringes, designed to address itching associated with atopic dermatitis. It's the pioneer antibody drug that blocks IL-31 signaling, a neuroimmune cytokine closely related to pruritus and skin inflammation in atopic dermatitis progression. The compound prevents IL-31 from binding with its receptor, thereby lowering itchiness and skin inflammation linked to atopic dermatitis.
Major companies operating in the pruritus therapeutic market include:
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Eli Lilly and Company
• Galderma Laboratories LP
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Abbott Laboratories
• Almirall SA
• Eisai Co. Ltd.
• Glenmark Pharmaceuticals Ltd.
• Ipca Laboratories Ltd.
• Lupin Chemicals Ltd.
• Cara Therapeutics Inc.
• EPI Health LLC
• AbbVie Inc.
• Albireo Pharma Inc.
• Bayer AG
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Huapont Life Sciences Co. Ltd.
• LEO Pharma AS
• MC2 Therapeutics Ltd.
• Novan Inc.
• Trevi Therapeutics Inc.
• UCB SA
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
North America was the largest region in the pruritus therapeutic market in 2024. The regions covered in the pruritus therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa